Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
How Has The Intravenous Iron Drugs Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In recent times, the market size for intravenous iron drugs has experienced significant growth. Expected to increase from $3.44 billion in 2024 to $3.84 billion in 2025, the market will embrace a compound annual growth rate (CAGR) of 11.6%. Factors that contributed to the growth in the historical period include the rising instances of iron deficiency anemia and chronic diseases, the growth in healthcare expenditure, the aging demographic, and the escalating occurrence of targeted illnesses.
The market for intravenous iron medications is anticipated to experience a significant expansion in the coming years, surging to a value of $5.86 billion by 2029 with a compound annual growth rate (CAGR) of 11.2%. This anticipated growth during the projected period can be credited to factors such as governmental policies, advancements in the domain of IV iron medications, increased demand for these medicines, a rise in research and development activities, and enhancements in dispensation and composition. Furthermore, the major trends to be expected during the forecast period are inclusive of advanced intravenous iron treatments, progress in drug development, a transition towards more user-friendly iv iron therapies, strategic collaborations, partnerships and acquisitions, and innovative technologies in new drug delivery systems.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp
What Are the Core Growth Drivers Propelling the Intravenous Iron Drugs Market Forward?
The rise in cases of chronic kidney disease (CKD) is anticipated to drive the expansion of the intravenous iron drugs market in the future. CKD involves a gradual decline in kidney function over time, resulting in a compromised ability of the kidneys to effectively remove waste and excess fluids from the bloodstream. The escalating incidence of CKD can be attributed to increasing diabetes and hypertension rates that inflict long-term damage to the kidneys. Intravenous iron medications benefit CKD patients by replenishing deficient iron supplies, rectifying anemia, and boosting hemoglobin levels, thus augmenting oxygen transport and alleviating the requirement for erythropoiesis-stimulating agents. For example, as per the Australian Institute of Health and Welfare, a government organization based in Australia, mortality rates due to CKD elevated by 4.2% in 2021 and 6.2% in 2022. In 2022, CKD accounted for approximately 22,000 fatalities in Australia, constituting 11% of all deaths. Consequently, the escalating incidence of CKD is propelling the growth of the intravenous iron drugs market.
What Segment Types Define the Intravenous Iron Drugs Market Structure?
The intravenous iron drugs market covered in this report is segmented –
1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types
2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex
3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose
4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Intravenous Iron Drugs Market?
North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Intravenous Iron Drugs Market?
Leading enterprises in the intravenous iron drugs market are concentrating on pioneering novel therapies, including intravenous (IV) iron replacement therapy, with the aim of enhancing efficacy, safety and outcomes for patients. The said therapy is a medical procedure that provides iron straight into a patient’s bloodstream via intravenous infusion, targeting iron deficiency and anemia, specifically for individuals who can’t adequately absorb or endure oral iron supplements. As an example, in June 2023, a pharmaceutical firm from Japan, Daiichi Sankyo Company Limited, known for its groundbreaking drug development and healthcare solutions, declared that Injectafer (ferric carboxymaltose injection), used for treating iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to elevate their exercise capacity, had received approval by the U.S. Food and Drug Administration (FDA). Injectafer has a great reputation as an intravenous iron therapy for effectively restoring iron levels in patients who either do not respond well or are intolerant to oral iron supplements.
View the full report here:
https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report
What Is the Definition of the Intravenous Iron Drugs Market?
Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, especially in patients who cannot tolerate or do not respond adequately to oral iron supplements. These drugs work by rapidly increasing iron levels, facilitating hemoglobin production, and improving oxygen transport, alleviating symptoms such as fatigue and weakness.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23430
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model